Open AccessPartial splenic embolization with Glubran®2/Lipiodol® mixture for oncological patients with hypersplenism-related thrombocytopenia requiring systemic chemotherapy
Author(s) -
Romaric Loffroy,
Nicolas Falvo,
Motoki Nakaï,
Lorenzo Pescatori,
Serge Aho-Gléglé,
Sophie Gehin,
Pierre-Emmanuel Berthod,
Romaric Né,
Julie Vincent,
François Ghiringhelli,
Marco Midulla,
Olivier Chevallier
Publication year - 2019
Publication title -
quantitative imaging in medicine and surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 21
eISSN - 2223-4292
pISSN - 2223-4306
DOI - 10.21037/qims.2019.03.07
Subject(s) - medicine , lipiodol , cyanoacrylate , surgery , adverse effect , embolization , clinical endpoint , splenectomy , spleen , chemistry , adhesive , organic chemistry , layer (electronics) , randomized controlled trial
Partial splenic embolization (PSE) has been used to improve thrombocytopenia related to hypersplenism. The optimal embolic agent is still debated. The purpose of this study was to evaluate the safety, hematologic response and outcomes of PSE with cyanoacrylate glue for oncological patients with hypersplenism-related thrombocytopenia requiring systemic chemotherapy (SC).